Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Recent developments in the palliative treatment of breast cancer: ASCO 2013

Recent developments in the palliative treatment of breast cancer: ASCO 2013 special report memo (2013) 6:233–235 DOI 10.1007/s12254-013-0115-7 Recent developments in the palliative treatment of breast cancer: ASCO 2013 Edgar Petru · Tina Idris · Vassilliki Kolovetsiou · Eva Schest Received: 9 August 2013 / Accepted: 9 October 2013 / Published online: 29 October 2013 © Springer-Verlag Wien 2013 Abstract Abstract #555: Prognostic factors in HER2-negative Purpose Highly selected abstracts from the ASCO meet- breast cancer patients receiving first-line bevacizumab ing are reported. (BEV) plus non-anthracycline therapy were investigated. Results and conclusions Abstract #1040: Subgroup Negative factors were disease-free interval ≤  24 months, analysis of TURANDOT (first-line paclitaxel and beva- liver metastases or ≥  2 involved organs, triple-negativity cizumab (T + BEV) versus capecitabine and BEV) was and adjuvant taxanes/anthracyclines, respectively. Thus, presented; 130 patients had triple-negative disease. One- established prognostic factors were also confirmed in year overall survival of T + BEV-treated patients with BEV-treated patients. triple-negative disease was 78  %. Thus, T + BEV may rep- Abstract #1049: Subgroup analyses of the phase-III resent a preferred regimen. trial of eribulin versus capecitabine in metastatic breast Abstract #514: Evidence for drug penetration of cancer pre-treated with anthracyclines/taxanes was car- capecitabine and lapatinib was demonstrated in resected ried out. Overall http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Recent developments in the palliative treatment of breast cancer: ASCO 2013

Download PDF
3 pages

Loading next page...
 
/lp/springer-journals/recent-developments-in-the-palliative-treatment-of-breast-cancer-asco-rsgeeLzY60

References (6)

Publisher
Springer Journals
Copyright
Copyright © 2013 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-013-0115-7
Publisher site
See Article on Publisher Site

Abstract

special report memo (2013) 6:233–235 DOI 10.1007/s12254-013-0115-7 Recent developments in the palliative treatment of breast cancer: ASCO 2013 Edgar Petru · Tina Idris · Vassilliki Kolovetsiou · Eva Schest Received: 9 August 2013 / Accepted: 9 October 2013 / Published online: 29 October 2013 © Springer-Verlag Wien 2013 Abstract Abstract #555: Prognostic factors in HER2-negative Purpose Highly selected abstracts from the ASCO meet- breast cancer patients receiving first-line bevacizumab ing are reported. (BEV) plus non-anthracycline therapy were investigated. Results and conclusions Abstract #1040: Subgroup Negative factors were disease-free interval ≤  24 months, analysis of TURANDOT (first-line paclitaxel and beva- liver metastases or ≥  2 involved organs, triple-negativity cizumab (T + BEV) versus capecitabine and BEV) was and adjuvant taxanes/anthracyclines, respectively. Thus, presented; 130 patients had triple-negative disease. One- established prognostic factors were also confirmed in year overall survival of T + BEV-treated patients with BEV-treated patients. triple-negative disease was 78  %. Thus, T + BEV may rep- Abstract #1049: Subgroup analyses of the phase-III resent a preferred regimen. trial of eribulin versus capecitabine in metastatic breast Abstract #514: Evidence for drug penetration of cancer pre-treated with anthracyclines/taxanes was car- capecitabine and lapatinib was demonstrated in resected ried out. Overall

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Oct 29, 2013

There are no references for this article.